WOBURN, Mass.--(BUSINESS WIRE)--AdvanDx, Inc. announced today that it closed a $15 million Series C financing round from new investor bioMérieux and existing investors LD Pensions and SLS Venture. This latest financing will be used to accelerate the commercialization of AdvanDx’s product pipeline through its global sales and marketing operations as well as to expand its world class research and development activities. The funding follows the recent announcement of AdvanDx’s exclusive distribution partnership with bioMérieux for its PNA FISH™ rapid in vitro diagnostic products for positive blood cultures in the United States. Together with the funding, the distribution partnership secures a significant cash flow stream for AdvanDx.
